📊 TMDX Key Takeaways
Is TransMedics Group, Inc. (TMDX) a Good Investment?
TransMedics exhibits strong revenue growth (+37.1% YoY) and healthy gross margins (58.2%), indicating solid product-market fit in the medical device sector. However, negative free cash flow (-$12.1M) despite positive net income, combined with extremely poor capital efficiency (ROE 1.5%, ROA 0.5%), raises concerns about earnings quality and the sustainability of profitability given high capital intensity.
TransMedics Group, Inc. Key Strengths (TMDX)
- Strong revenue growth of 37.1% YoY demonstrates robust market demand
- Healthy gross margin of 58.2% indicates pricing power and cost management
- Fortress balance sheet with $461.7M cash, minimal debt ($58.8M), and 6.74x current ratio provides strategic flexibility
TMDX Stock Risks: TransMedics Group, Inc. Investment Risks
- Negative free cash flow of -$12.1M despite positive net income signals cash conversion problems and high capex burden relative to operating cash flow
- Extremely low returns on capital (ROE 1.5%, ROA 0.5%) indicate poor capital deployment efficiency and value creation
- Low interest coverage ratio of 1.8x and thin net margin of 4.2% limit financial flexibility despite strong balance sheet
Key Metrics to Watch
- Free cash flow sustainability and capex intensity relative to revenue growth
- Operating cash flow conversion rates and cash-to-earnings quality
- Return on equity and asset turnover trends as profitability scales
TransMedics Group, Inc. (TMDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.74x current ratio provides a solid financial cushion.
TMDX Profit Margin, ROE & Profitability Analysis
TMDX vs Healthcare Sector: How TransMedics Group, Inc. Compares
How TransMedics Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TransMedics Group, Inc. Stock Overvalued? TMDX Valuation Analysis 2026
Based on fundamental analysis, TransMedics Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TransMedics Group, Inc. Balance Sheet: TMDX Debt, Cash & Liquidity
TMDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TransMedics Group, Inc.'s revenue has grown significantly by 21% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.77 indicates the company is currently unprofitable.
TMDX Revenue Growth, EPS Growth & YoY Performance
TMDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $143.5M | $7.3M | $0.20 |
| Q3 2025 | $108.8M | $4.2M | $0.12 |
| Q2 2025 | $114.3M | $12.2M | $0.35 |
| Q1 2025 | $96.9M | $12.2M | $0.35 |
| Q3 2024 | $66.4M | -$1.0M | $0.12 |
| Q2 2024 | $52.5M | -$1.0M | $-0.03 |
| Q1 2024 | $41.6M | -$2.6M | $-0.08 |
| Q3 2023 | $25.7M | -$1.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TransMedics Group, Inc. Dividends, Buybacks & Capital Allocation
TMDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TransMedics Group, Inc. (CIK: 0001756262)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TMDX
What is the AI rating for TMDX?
TransMedics Group, Inc. (TMDX) has an AI grade of B with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TMDX's key strengths?
Claude: Strong revenue growth of 37.1% YoY demonstrates robust market demand. Healthy gross margin of 58.2% indicates pricing power and cost management.
What are the risks of investing in TMDX?
Claude: Negative free cash flow of -$12.1M despite positive net income signals cash conversion problems and high capex burden relative to operating cash flow. Extremely low returns on capital (ROE 1.5%, ROA 0.5%) indicate poor capital deployment efficiency and value creation.
What is TMDX's revenue and growth?
TransMedics Group, Inc. reported revenue of $173.9M.
Does TMDX pay dividends?
TransMedics Group, Inc. does not currently pay dividends.
Where can I find TMDX SEC filings?
Official SEC filings for TransMedics Group, Inc. (CIK: 0001756262) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TMDX's EPS?
TransMedics Group, Inc. has a diluted EPS of $0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TMDX's fundamental grade?
Based on our AI fundamental analysis in June 2026, TransMedics Group, Inc. has a B grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TMDX stock overvalued or undervalued?
Valuation metrics for TMDX: ROE of 1.5% (sector avg: 15%), net margin of 4.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TMDX's AI grade for 2026?
Our dual AI analysis gives TransMedics Group, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TMDX's free cash flow?
TransMedics Group, Inc.'s operating cash flow is $24.5M, with capital expenditures of $36.7M. FCF margin is -7.0%.
How does TMDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.2% (avg: 12%), ROE 1.5% (avg: 15%), current ratio 6.74 (avg: 2).